Your browser doesn't support javascript.
Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection.
Rabie, Al Shaimaa Ibrahim; Salah, Hager; Said, Amira S A; Shaaban, Ahmed Hassan; Abdou, Lamya Mohamed; Khalil, Doaa Mahmoud; Kharaba, Zelal; Afifi, Hala; Sofy, Mahmoud R; Youssef, Eman M I; Bayoumy, Eman S M; Hussein, Raghda R S.
  • Rabie ASI; Clinical Pharmacy Department, Fayium Oncology Center, Fayium 63511, Egypt.
  • Salah H; Clinical Nutrition Department, Fayium Health Insurance Authority, Fayium 63511, Egypt.
  • Said ASA; Pharmaceutical Services Department, King Hamad University Hospital, Al Sayh 24343, Bahrain.
  • Shaaban AH; Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
  • Abdou LM; Department of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, Abu Dhabi 64141, United Arab Emirates.
  • Khalil DM; Clinical Oncology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62514, Egypt.
  • Kharaba Z; Internal Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62514, Egypt.
  • Afifi H; Public Health and Community Medicine Department, Faculty of Medicine, Beni-Seuf University, Beni-Suef 62514, Egypt.
  • Sofy MR; Department of Clinical Pharmacy, College of Pharmacy, Al Ain University, Al Ain, Abu Dhabi 64141, United Arab Emirates.
  • Youssef EMI; AAU Health and Biomedical Centre, Al Ain University, Al Ain, Abu Dhabi 64141, United Arab Emirates.
  • Bayoumy ESM; Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne NE2 4HH, UK.
  • Hussein RRS; College of Dental Surgery, City University Ajman, Ajman 18484, United Arab Emirates.
Healthcare (Basel) ; 11(4)2023 Feb 17.
Article in English | MEDLINE | ID: covidwho-2244435
ABSTRACT
There seem to currently be no therapeutic medications found for the severe coronavirus infection in 2019 (COVID-19). In light of this, it has been hypothesized that the immunomodulatory treatment known as tocilizumab can lessen the inflammatory response that occurs in the respiratory system, speed up the process of clinical benefit, lower the risk of death, and avert the need for ventilators. This randomized controlled trial (RCT) studied patients with a proven infection of SARS-CoV-2 and hyperinflammatory reactions. The inclusion criteria included fever (body temperature > 38 °C), pulmonary infiltrates, or supplemental oxygen. The patients received either conventional treatment with one dose of either tocilizumab (8 mg per kilogram of body weight) or conventional treatment only. The subjects were randomized to receive either treatment with a 11 ratio. A time-to-event test was conducted to determine the time to intubation or death. There was an insignificant difference between the investigated groups regarding the time to death, time to mechanical ventilation, and percentage of deaths. The conventional group's median (IQR) hospital length of stay was 4 (3-6) days, whereas the tocilizumab therapy group was 7 (4.75-10) days. There was a substantial difference in the mechanical ventilation rates in both groups, which were 17 (34%) and 28 (56%), respectively. In hospitalized patients with severe illness and COVID-19, tocilizumab was ineffective in preventing intubation or death. Trials must be larger, however, in order to exclude the potential benefits or harms.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2023 Document Type: Article Affiliation country: Healthcare11040607

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2023 Document Type: Article Affiliation country: Healthcare11040607